A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New … (NCT07235293) | Clinical Trial Compass
RecruitingPhase 2
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
United States90 participantsStarted 2026-01-16
Plain-language summary
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Are ≥ 18 years of age with a life expectancy of \> 3 months.
✓. Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy).
✓. Measurable disease per RECIST v1.1.
Exclusion criteria
✕. Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids.
✕. Unresolved AEs of Grade 2 or higher from prior anticancer therapy.
✕. Past or current history of autoimmune disease or immune deficiency.
✕. History of other malignancy within 3 years of first study treatment cycle.
✕. Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies (prior treatment with CPIs is not exclusory).
✕
What they're measuring
1
To determine Median overall survival (mOS) in participants treated with the combination of DSP107 and atezolizumab versus fruquintinib.
Timeframe: From Day 1 until date of death from any cause assessed up to 2 years